Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma (NASDAQ: CUE) reported its Q1 2025 financial results and business highlights. The company secured a strategic collaboration with Boehringer Ingelheim for CUE-501, receiving a $12 million upfront payment with potential milestone payments of ~$345 million. The company also raised ~$20 million through a follow-on offering.
Q1 2025 financial results showed revenue of $0.4 million, down from $1.7 million in Q1 2024. R&D expenses decreased to $8.5 million from $10.2 million, while G&A expenses remained stable at $4.2 million. As of March 31, 2025, cash and equivalents stood at $13.1 million, with an additional $30 million received in April from the public offering and Boehringer Ingelheim partnership.
The company regained worldwide rights for CUE-401, its lead autoimmune program, and plans a virtual event on May 15, 2025, featuring key opinion leaders to discuss their immunology pipeline.
Cue Biopharma (NASDAQ: CUE) ha comunicato i risultati finanziari del primo trimestre 2025 e i principali eventi aziendali. La società ha siglato una collaborazione strategica con Boehringer Ingelheim per CUE-501, ricevendo un pagamento iniziale di 12 milioni di dollari e potenziali pagamenti legati a traguardi per circa 345 milioni di dollari. Inoltre, ha raccolto circa 20 milioni di dollari tramite un'offerta successiva.
I risultati finanziari del primo trimestre 2025 mostrano ricavi pari a 0,4 milioni di dollari, in calo rispetto a 1,7 milioni nel primo trimestre 2024. Le spese per ricerca e sviluppo sono diminuite a 8,5 milioni da 10,2 milioni, mentre le spese generali e amministrative sono rimaste stabili a 4,2 milioni. Al 31 marzo 2025, la liquidità e equivalenti ammontavano a 13,1 milioni di dollari, con ulteriori 30 milioni ricevuti ad aprile dall'offerta pubblica e dalla partnership con Boehringer Ingelheim.
La società ha riacquisito i diritti mondiali su CUE-401, il suo programma principale per le malattie autoimmuni, e prevede un evento virtuale il 15 maggio 2025 con esperti di rilievo per discutere il suo portafoglio di immunologia.
Cue Biopharma (NASDAQ: CUE) informó sus resultados financieros del primer trimestre de 2025 y los aspectos destacados del negocio. La compañía aseguró una colaboración estratégica con Boehringer Ingelheim para CUE-501, recibiendo un pago inicial de 12 millones de dólares y posibles pagos por hitos de aproximadamente 345 millones de dólares. Además, recaudó alrededor de 20 millones de dólares mediante una oferta secundaria.
Los resultados financieros del primer trimestre de 2025 mostraron ingresos de 0,4 millones de dólares, una disminución respecto a los 1,7 millones del primer trimestre de 2024. Los gastos en I+D disminuyeron a 8,5 millones desde 10,2 millones, mientras que los gastos generales y administrativos se mantuvieron estables en 4,2 millones. Al 31 de marzo de 2025, el efectivo y equivalentes eran de 13,1 millones de dólares, con 30 millones adicionales recibidos en abril por la oferta pública y la asociación con Boehringer Ingelheim.
La compañía recuperó los derechos mundiales de CUE-401, su programa principal para enfermedades autoinmunes, y planea un evento virtual el 15 de mayo de 2025 con líderes de opinión clave para discutir su cartera de inmunología.
Cue Biopharma(NASDAQ: CUE)는 2025년 1분기 재무 실적 및 주요 사업 내용을 발표했습니다. 회사는 CUE-501에 대해 Boehringer Ingelheim과 전략적 협력을 체결하여 1,200만 달러의 선급금을 받고 약 3억 4,500만 달러 규모의 마일스톤 지급 가능성을 확보했습니다. 또한 후속 공모를 통해 약 2,000만 달러를 조달했습니다.
2025년 1분기 재무 결과는 매출 40만 달러로, 2024년 1분기 170만 달러에서 감소했습니다. 연구개발비는 850만 달러로 1,020만 달러에서 줄었고, 일반관리비는 420만 달러로 안정적으로 유지되었습니다. 2025년 3월 31일 기준 현금 및 현금성 자산은 1,310만 달러이며, 4월에 공모 및 Boehringer Ingelheim 파트너십으로부터 추가 3,000만 달러를 받았습니다.
회사는 자가면역 질환 주요 프로그램인 CUE-401에 대한 전 세계 권리를 다시 확보했으며, 2025년 5월 15일 주요 의견 리더들과 함께 면역학 파이프라인을 논의하는 가상 이벤트를 계획하고 있습니다.
Cue Biopharma (NASDAQ : CUE) a publié ses résultats financiers du premier trimestre 2025 et les faits marquants de son activité. La société a conclu une collaboration stratégique avec Boehringer Ingelheim pour CUE-501, recevant un paiement initial de 12 millions de dollars ainsi que des paiements potentiels liés à des jalons d'environ 345 millions de dollars. Elle a également levé environ 20 millions de dollars via une offre secondaire.
Les résultats financiers du premier trimestre 2025 montrent un chiffre d'affaires de 0,4 million de dollars, en baisse par rapport à 1,7 million au premier trimestre 2024. Les dépenses de R&D ont diminué à 8,5 millions contre 10,2 millions, tandis que les frais généraux et administratifs sont restés stables à 4,2 millions. Au 31 mars 2025, la trésorerie et équivalents s’élevaient à 13,1 millions de dollars, avec un complément de 30 millions reçu en avril grâce à l’offre publique et au partenariat avec Boehringer Ingelheim.
La société a récupéré les droits mondiaux sur CUE-401, son programme principal en auto-immunité, et prévoit un événement virtuel le 15 mai 2025 avec des leaders d’opinion clés pour discuter de son pipeline en immunologie.
Cue Biopharma (NASDAQ: CUE) veröffentlichte seine Finanzergebnisse für das erste Quartal 2025 sowie wichtige Geschäftshighlights. Das Unternehmen sicherte sich eine strategische Zusammenarbeit mit Boehringer Ingelheim für CUE-501 und erhielt eine Vorauszahlung von 12 Millionen US-Dollar sowie potenzielle Meilensteinzahlungen von rund 345 Millionen US-Dollar. Zudem wurden etwa 20 Millionen US-Dollar durch eine Kapitalerhöhung eingenommen.
Die Finanzergebnisse für das erste Quartal 2025 zeigten einen Umsatz von 0,4 Millionen US-Dollar, gegenüber 1,7 Millionen US-Dollar im ersten Quartal 2024. Die F&E-Ausgaben sanken von 10,2 Millionen auf 8,5 Millionen US-Dollar, während die Verwaltungs- und Gemeinkosten stabil bei 4,2 Millionen US-Dollar blieben. Zum 31. März 2025 betrugen die liquiden Mittel 13,1 Millionen US-Dollar, zusätzlich wurden im April 30 Millionen US-Dollar aus dem öffentlichen Angebot und der Partnerschaft mit Boehringer Ingelheim erhalten.
Das Unternehmen hat die weltweiten Rechte an CUE-401, seinem führenden Autoimmunprogramm, zurückerlangt und plant für den 15. Mai 2025 eine virtuelle Veranstaltung mit wichtigen Meinungsführern zur Diskussion seiner Immunologie-Pipeline.
- Strategic collaboration with Boehringer Ingelheim for CUE-501 with $12M upfront payment and potential $345M in milestone payments
- Successfully raised ~$20M in follow-on capital raise
- Reduction in R&D expenses by 16.2% year-over-year
- Regained worldwide rights for lead autoimmune program CUE-401
- Additional $30M cash injection in April 2025 strengthening balance sheet
- Revenue declined 75.5% year-over-year to $0.4M from $1.7M
- Net loss of $12.3M in Q1 2025
- Termination of Ono Pharmaceutical agreement in March 2025
- Going concern warning about insufficient capital for operations beyond 12 months
Insights
Cue Biopharma strengthens financial position through strategic partnership and capital raise, offsetting concerning Q1 financial metrics.
Cue Biopharma's Q1 results showcase strategic repositioning despite ongoing financial challenges. The Boehringer Ingelheim collaboration for CUE-501, worth
The financial metrics reveal concerning trends: quarterly revenue dropped
Regaining worldwide rights to CUE-401 for autoimmune diseases allows strategic flexibility but now places development costs solely on Cue's shoulders. This asset's potential will depend heavily on the upcoming KOL event showcasing preclinical data. With approximately
The
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of
Raised gross proceeds of ~
Successfully regained worldwide rights for lead autoimmune program, CUE-401, with potential to become a new standard of care for autoimmune and inflammatory diseases
Virtual Event planned for May 15, 2025 at 11 AM ET, featuring two prominent Key Opinion Leaders in the field of Immunology
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today reported first quarter 2025 financial results.
“We made notable and encouraging progress during the first quarter of 2025 and believe we are well positioned to further our corporate objectives,” said Daniel Passeri, chief executive officer of Cue Biopharma. “We believe the strategic collaboration with Boehringer Ingelheim for CUE-501 combined with our capital raise, places us in a position of strength to advance CUE-401 toward the clinic while exploring additional portfolio optimization and partnering opportunities.”
Upcoming Event
Novel Biologics Portfolio Virtual Event planned for May 15, 2025 at 11 AM ET: Cue Biopharma’s virtual event will feature two key opinion leaders (KOLs): Richard DiPaolo, PhD (Saint Louis University) and Andrew Cope, MD, PhD (Centre for Rheumatic Diseases, King's College London). The event will highlight new preclinical data for CUE-401, as well as provide an overview of the CUE-500 program and include key updates on the CUE-100 series clinical oncology programs.
The live and archived virtual event will also be available in the News + Publications section of the Company’s website. The webcast will be archived for 30 days.
First Quarter 2025 Financial Results
The Company reported revenue of
Research and development expenses were
General and administrative expenses were
As of March 31, 2025, the Company had
| Cue Biopharma, Inc. | ||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (Unaudited, In thousands, except share and per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Collaboration revenue | $ | 421 | $ | 1,717 | ||||
| Operating expenses: | ||||||||
| General and administrative | 4,173 | 4,186 | ||||||
| Research and development | 8,547 | 10,199 | ||||||
| Total operating expenses | 12,720 | 14,385 | ||||||
| Loss from operations | (12,299 | ) | (12,668 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 170 | 562 | ||||||
| Interest expense | (128 | ) | (241 | ) | ||||
| Total other income, net | 42 | 321 | ||||||
| Net loss | $ | (12,257 | ) | $ | (12,347 | ) | ||
| Comprehensive loss | $ | (12,257 | ) | $ | (12,347 | ) | ||
| Net loss per common share – basic and diluted | $ | (0.17 | ) | $ | (0.25 | ) | ||
| Weighted average common shares outstanding – basic and diluted | 74,254,700 | 49,466,711 | ||||||
| Cue Biopharma, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited, In thousands) | ||||||||
| March 31, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 13,136 | $ | 22,459 | ||||
| Other assets | 9,118 | 9,732 | ||||||
| Total assets | $ | 22,254 | $ | 32,191 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Liabilities | $ | 15,674 | $ | 14,692 | ||||
| Stockholders' equity | 6,580 | 17,499 | ||||||
| Total Liabilities and stockholders’ equity | $ | 22,254 | $ | 32,191 | ||||
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the Company’s belief that CUE-401 has potential to transform treatment across a broad spectrum of autoimmune and inflammatory diseases; the potential therapeutic benefits of CUE-501 and the CUE-500 series; the Company’s ability to advance its Immuno-STAT™ platform; and the Company’s business strategies, plans and prospects, including the Company’s plans to advance CUE-401 toward the clinic and explore additional portfolio optimization and partnering opportunities. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and a history of losses; the Company’s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current “going concern” determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the Company’s ability to achieve profitability; potential setbacks in the Company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the Company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; the Company’s ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the Company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the Company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the Company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
What is the financial impact of Cue Biopharma's (CUE) Boehringer Ingelheim collaboration in 2025?
How much did Cue Biopharma (CUE) raise in their Q1 2025 capital raise?
What were Cue Biopharma's (CUE) Q1 2025 revenue and losses?
How much cash does Cue Biopharma (CUE) have as of March 2025?
What happened to Cue Biopharma's (CUE) partnership with Ono Pharmaceutical?
